This is quite a strange contention to hold - by suggesting they can wait this long the implication is that you disagree with the Jasmin's of this world and they won't need working capital (I agree) and cost/income from business growth will mean CFN or even profits before year end (again I agree). So perhaps you foresee a big commercial order for chemistry needing funding? It seems Alexium could accommodate the cost of servicing a $750,000 order so one presumes the cash situation is more than sustainable. The longer recurrent business grows for the more likely that future expansion can be internally funded without the need for capital raising and the likes - so again, could you expand upon your logic?
I'm also interested by your comment on a rising share price facilitating a CR - what do you think will justify the price rise, and why will the price be rising if a CR is needed?
AJX Price at posting:
52.0¢ Sentiment: Hold Disclosure: Held
